141 related articles for article (PubMed ID: 22726382)
1. Current practice of chronic hepatitis B treatment in Southern Italy.
Stroffolini T; Spadaro A; Di Marco V; Scifo G; Russello M; Montalto G; Bertino G; Surace L; Caroleo B; Foti G; Portelli V; Madonia S; Sapienza M; Cosco L; Frugiuele P; Galdieri A; Brandolino N; Siciliano R; Bruno S; Almasio PL;
Eur J Intern Med; 2012 Jul; 23(5):e124-7. PubMed ID: 22726382
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
Buster EH; Schalm SW; Janssen HL
Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Soriano V; Tuma P; Vispo E; Labarga P; Fernández JV; Medrano J; Barreiro P
J HIV Ther; 2009 Mar; 14(1):13-8. PubMed ID: 19731560
[TBL] [Abstract][Full Text] [Related]
4. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog.
Chen X; Cao Z; Liu Y; Zhang H; Zhang Y; Ma L; Jin Y; Yu H; Ma B; Zheng Y; Wu H
J Gastroenterol Hepatol; 2012 Mar; 27(3):481-6. PubMed ID: 22098411
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological agents for the treatment of chronic hepatitis B].
Sánchez-Tapias JM
Gastroenterol Hepatol; 2008 Mar; 31(3):120-8. PubMed ID: 18341843
[No Abstract] [Full Text] [Related]
6. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines.
Colle I; Adler M; Brenard R; Henrion J; Langlet P; Michielsen P; Orlent H; Reynaert H; Sprengers D; Stärkel P; Van Damme P; Verslype C; Delwaide J;
Acta Gastroenterol Belg; 2007; 70(4):389-420. PubMed ID: 18330099
[No Abstract] [Full Text] [Related]
7. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
Viganò M; Invernizzi F; Lampertico P
Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
[TBL] [Abstract][Full Text] [Related]
8. HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?
Buti M
Liver Int; 2014 Feb; 34 Suppl 1():108-11. PubMed ID: 24373086
[TBL] [Abstract][Full Text] [Related]
9. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
10. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
Viganò M; Mangia G; Lampertico P
Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
[TBL] [Abstract][Full Text] [Related]
11. [Interferon-based versus direct antiviral therapy in patients with chronic hepatitis B].
Tornai I
Orv Hetil; 2011 May; 152(22):869-74. PubMed ID: 21565754
[TBL] [Abstract][Full Text] [Related]
12. Review article: current antiviral therapy of chronic hepatitis B.
Ayoub WS; Keeffe EB
Aliment Pharmacol Ther; 2008 Jul; 28(2):167-77. PubMed ID: 18466358
[TBL] [Abstract][Full Text] [Related]
13. Antiviral treatment for chronic hepatitis B virus infection--immune modulation or viral suppression?
Buster EH; Janssen HL
Neth J Med; 2006 Jun; 64(6):175-85. PubMed ID: 16788215
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
15. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA.
Lu J; Zhang S; Liu Y; Du X; Ren S; Zhang H; Ma L; Chen Y; Chen X; Shen C
Liver Int; 2015 Jun; 35(6):1692-9. PubMed ID: 25438657
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?].
Fuentes Olmo J; Uribarrena Amézaga R
Gastroenterol Hepatol; 2011; 34(7):492-503. PubMed ID: 21550145
[TBL] [Abstract][Full Text] [Related]
17. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
Rijckborst V; Sonneveld MJ; Janssen HL
Aliment Pharmacol Ther; 2011 Mar; 33(5):501-13. PubMed ID: 21198707
[TBL] [Abstract][Full Text] [Related]
18. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Leung N
Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic perspectives in HBV: when to stop NAs.
Pérez-Cameo C; Pons M; Esteban R
Liver Int; 2014 Feb; 34 Suppl 1():146-53. PubMed ID: 24373092
[TBL] [Abstract][Full Text] [Related]
20. [Protocol for the antiviral therapy of chronic hepatitis B].
;
Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
